ITGAE and ulcerative colitis: One such approach that is currently being developed is the use of specific anti-integrins, controlling both inflammatory effects and immune cell trafficking: Etrolizumab, a monoclonal antibody targeting the two integrins CD103 and α4β7, led to clinical remission in patients with ulcerative colitis in a phase 2 trial, and consecutive phase 3 trials are ongoing [40].